Copyright 2019 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.26% per year. These returns cover a period from January 1, 1988 through December 3, 2018. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
biotechs: Archive
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
by Zacks Equity Research
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
AZN RHHBY CLVS IMMU
biotechs
Ligand (LGND) Takes a Hit on Citron's Negative Research Report
by Zacks Equity Research
Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.
LLY BMY LGND SAGE
biotechs
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
by Zacks Equity Research
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
ACAD EXEL VNDA AMGN
biotechs
Regeneron (REGN) Sails Steady on Label Expansion of Drugs
by Zacks Equity Research
Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.
BAYRY SNY REGN CELG
biotechs
Will Dividend Stocks be the Hot Stocks of 2019?
by Tracey Ryniec
With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.
ABBV T VZ GILD OXY
biotechs oil-energy tech-stocks
Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
by Zacks Equity Research
Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.
RHHBY BMY BAYRY EXEL
biotechs
Pfizer Gets FDA's Priority Review for Rare Disease Candidate
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
PFE ALNY IONS AKCA
biotechs
5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
by Zacks Equity Research
Exelixis (EXEL) lead drug, Cabometyx continues to perform well.
BMY RHHBY MRK EXEL
biotechs
Tilray Shares Rally as Investor Plans Not to Sell Shares
by Zacks Equity Research
Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.
NVS BUD CRON CGC TLRY
biotechs
Top ETFs of Last Week
by Sanghamitra Saha
These ETFs have had a strong last week.
DIA SBIO SPY QQQ EBIZ MJ XKST BMLP
biotechs etfs marijuana retail tech-stocks
Best & Worst Performing ETFs to Start 2019
by Sweta Killa
We have highlighted some ETFs that are off to a good start in 2019 and some that have had a rough start.
XES MJ ARKG VXXB BDRY DWSH
biotechs etfs marijuana oil-energy
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
by Zacks Equity Research
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.
RHHBY ACOR VNDA ASLN
biotechs
Options Traders Expect Huge Moves in Ferroglobe (GSM) Stock
by Zacks Equity Research
Investors need to pay close attention to Ferroglobe (GSM) stock based on the movements in the options market lately.
GSM
biotechs
NASH Space in Focus in 2019 as Firms Look to Diversify
by Zacks Equity Research
NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.
PFE RHHBY MRK NVS VKTX GILD ICPT
biotechs
Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.
LLY RHHBY NVS PBYI
biotechs
Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
by Zacks Equity Research
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.
PFE BMY AMRN CELG
biotechs
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
JNJ GSK PFE BMY MRK LLY CELG
biotechs pharmaceuticals
Athenex Completes Enrollment Target for Breast Cancer Study
by Zacks Equity Research
Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.
RHHBY PFE PBYI ATNX
biotechs
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
by Zacks Equity Research
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
ACOR VNDA INO MYL
biotechs
Moderna (MRNA) Announces Pipeline Progress, Shares Rise
by Zacks Equity Research
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
MRK AZN VRTX MRNA
biotechs
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
by Zacks Equity Research
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
AMGN VNDA INO AEZS
biotechs
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
by Zacks Equity Research
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
REGN GILD ALNY CELG BIIB LOXO SAGE
biotechs
Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
MRTX ACOR
biotechs
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
by Zacks Equity Research
Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.
BMY BLUE XLRN CELG
biotechs
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
SNY GSK EBS VNDA
biotechs